Table 9 Percent tumor reduction in HCC1954 xenograft model treated with HER-specific and c-MET specific antagonists
Drug arm vs. comparator arm | Tumor reduction (t test) |
|---|---|
Tepotinib versus control | 10% (p = 0.780) |
Neratinib versus control | 54% (p = 0.003) |
Neratinib + tepotinib versus control | 71% (p = 0.0003) |
Neratinib + tepotinib versus neratinib | 37% (p = 0.05) |
Erlotinib versus control | 5% (p = 0.870) |
Erlotinib + tepotinib versus control | 51% (p = 0.110) |